These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 14573759)

  • 1. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
    Incles CM; Schultes CM; Kelland LR; Neidle S
    Mol Pharmacol; 2003 Nov; 64(5):1101-8. PubMed ID: 14573759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function.
    Burger AM; Dai F; Schultes CM; Reszka AP; Moore MJ; Double JA; Neidle S
    Cancer Res; 2005 Feb; 65(4):1489-96. PubMed ID: 15735037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
    Raju U; Nakata E; Mason KA; Ang KK; Milas L
    Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
    Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.
    Smith V; Raynaud F; Workman P; Kelland LR
    Mol Pharmacol; 2001 Nov; 60(5):885-93. PubMed ID: 11641415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
    Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
    J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
    Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
    Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
    Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
    FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
    Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
    Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of acridine-based telomerase inhibition and telomere shortening.
    Gunaratnam M; Greciano O; Martins C; Reszka AP; Schultes CM; Morjani H; Riou JF; Neidle S
    Biochem Pharmacol; 2007 Sep; 74(5):679-89. PubMed ID: 17631279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhabdoid tumor growth is inhibited by flavopiridol.
    Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
    Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
    Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI
    Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.
    Chao SH; Fujinaga K; Marion JE; Taube R; Sausville EA; Senderowicz AM; Peterlin BM; Price DH
    J Biol Chem; 2000 Sep; 275(37):28345-8. PubMed ID: 10906320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
    Motwani M; Li X; Schwartz GK
    Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
    Ambrosini G; Seelman SL; Qin LX; Schwartz GK
    Cancer Res; 2008 Apr; 68(7):2312-20. PubMed ID: 18381438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
    Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
    J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
    Li W; Fan J; Bertino JR
    Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavopiridol binds to duplex DNA.
    Bible KC; Bible RH; Kottke TJ; Svingen PA; Xu K; Pang YP; Hajdu E; Kaufmann SH
    Cancer Res; 2000 May; 60(9):2419-28. PubMed ID: 10811119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
    Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
    Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.